Dr. Ebrahim S. Delpassand

Nuclear Medicine
Baylor College Of Medicine
1 Baylor Plz, 
Houston, TX 
Accepting New Patients
Baylor College Of Medicine
1 Baylor Plz, 
Houston, TX 

Overview

Ebrahim Delpassand is a Nuclear Medicine provider practicing medicine in Houston, Texas.

His clinical expertise encompasses Pancreatic Ductal Adenocarcinoma and Liver Embolization.

He is actively involved in clinical research, co-authoring 30 peer reviewed articles and participating in 5 clinical trials. Dr. Delpassand is currently accepting new patients.

Specialties

Nuclear Medicine

Licenses

Nuclear Radiology in TX

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Community Health Choice
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 4 Less Insurance Carriers -

Locations

Baylor College of Medicine
1 Baylor Plz, Houston, TX 77030
Other Locations
Sightline of Atlanta LLP
9701 Richmond Ave Ste 122, Houston, TX 77042

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

An Open-label, Single-dose, Clinical Trial of 68Ga-DOTATATE (GalioMedix™) PET-CT Scan for Diagnosis of Primary and Metastatic Somatostatin Receptor-positive Neuroendocrine Tumors (NETs)
An Open-label, Single-dose, Clinical Trial of 68Ga-DOTATATE (GalioMedix™) PET-CT Scan for Diagnosis of Primary and Metastatic Somatostatin Receptor-positive Neuroendocrine Tumors (NETs)
Enrollment Status: Completed
Publish Date: August 06, 2025
Intervention Type: Diagnostic test, Drug
Study Phase: Not Applicable
VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Drug, Other
Study Drug: 177Lu-PSMA-617
Study Phase: Phase 3
A Phase II, Non-Randomized, Open-Label, Single-center, Physician Sponsored Study to Determine the Safety and Effectiveness of Lu-177 DOTATOC in Adult Subjects With Somatostatin Receptor Expressing Pulmonary, Pheochromocytoma, paragangliomUnknown Primary, and Thymus Neuroendocrine Tumors (PUTNET) or Any Other Non-.GEP-NET.
A Phase II, Non-Randomized, Open-Label, Single-center, Physician Sponsored Study to Determine the Safety and Effectiveness of Lu-177 DOTATOC in Adult Subjects With Somatostatin Receptor Expressing Pulmonary, Pheochromocytoma, paragangliomUnknown Primary, and Thymus Neuroendocrine Tumors (PUTNET) or Any Other Non-.GEP-NET.
Enrollment Status: Withdrawn
Publish Date: March 10, 2023
Intervention Type: Drug
Study Drug: 177Lu-DOTATOC
Study Phase: Phase 2
PSMA-directed endoRadiothErapy of Castration-reSISTant Prostate Cancer (RESIST-PC). A Phase II Clinical Trial
PSMA-directed endoRadiothErapy of Castration-reSISTant Prostate Cancer (RESIST-PC). A Phase II Clinical Trial
Enrollment Status: Terminated
Publish Date: March 24, 2021
Intervention Type: Drug
Study Phase: Phase 2
68Ga-PSMA (ProstaMedix™) PET-CT Scan for Diagnosis and Management of Prostate Cancer
68Ga-PSMA (ProstaMedix™) PET-CT Scan for Diagnosis and Management of Prostate Cancer
Enrollment Status: Unknown
Publish Date: August 19, 2020
Intervention Type: Drug
Study Drug: 68Ga-PSMA
Study Phase: Phase 2
View 4 Less Clinical Trials

30 Total Publications

Tumor and Organ Dose Estimates from 177Lu-PSMA-617 Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: Results from the RESIST-PC Phase 2 Trial.
Tumor and Organ Dose Estimates from 177Lu-PSMA-617 Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: Results from the RESIST-PC Phase 2 Trial.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: March 23, 2026
Similar Doctors
Expertise in
8
conditions
Dr. Homer A. Macapinlac
Nuclear Medicine
Expertise in
8
conditions
Dr. Homer A. Macapinlac
Nuclear Medicine
Referral may be required

MD Anderson Clinical Care Center-Woodlands

100 Fellowship Dr, 
Conroe, TX 
 (36.6 miles away)
713-563-0050
Languages Spoken:
English
See accepted insurances

Homer Macapinlac is a Nuclear Medicine provider practicing medicine in Conroe, Texas. Dr. Macapinlac is highly rated in 8 conditions, according to our data. His clinical expertise encompasses T-Cell Lymphoma, Muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer, and Classical Hodgkin Lymphoma.

Expertise in
3
conditions
Dr. Aaron C. Jessop
Nuclear Medicine
Expertise in
3
conditions
Dr. Aaron C. Jessop
Nuclear Medicine
Referral may be required

Office

1515 Holcombe Blvd Unit 1264, 
Houston, TX 
 (0.4 miles away)
713-563-3697
Languages Spoken:
English
See accepted insurances

Aaron Jessop is a Nuclear Medicine provider practicing medicine in Houston, Texas. Dr. Jessop is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Melorheostosis, Melorheostosis with Osteopoikilosis, Osteopenia, and Lung Nodules.

Expertise in
4
conditions
Dr. Hubert H. Chuang
Nuclear Medicine
Expertise in
4
conditions
Dr. Hubert H. Chuang
Nuclear Medicine
Referral may be required

MD Anderson Clinical Care Center-Woodlands

100 Fellowship Dr, 
Conroe, TX 
 (36.6 miles away)
713-563-0050
Languages Spoken:
English
See accepted insurances

Hubert Chuang is a Nuclear Medicine provider practicing medicine in Conroe, Texas. Dr. Chuang is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Classical Hodgkin Lymphoma, Melorheostosis, Melorheostosis with Osteopoikilosis, and Osteopenia.

Frequently Asked Questions about Dr. Ebrahim S. Delpassand

How do I make an appointment with Dr. Ebrahim S. Delpassand?

You can book an appointment with Dr. Ebrahim S. Delpassand by calling their office at 713-793-3615. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Ebrahim S. Delpassand a top-rated expert for Pancreatic Ductal Adenocarcinoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Ebrahim S. Delpassand is classified as an Experienced expert for Pancreatic Ductal Adenocarcinoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Ebrahim S. Delpassand specialize in?

While Dr. Ebrahim S. Delpassand is a Nuclear Medicine, they have specific expertise in Pancreatic Ductal Adenocarcinoma, Liver Embolization. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Nuclear Medicine.

Does Dr. Ebrahim S. Delpassand participate in research or clinical trials?

Yes. Dr. Ebrahim S. Delpassand has published 30 articles and abstracts on conditions like Pancreatic Ductal Adenocarcinoma. You can view a list of Dr. Ebrahim S. Delpassand's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Ebrahim S. Delpassand accept my insurance?

Dr. Ebrahim S. Delpassand accepts most major insurance plans, including Aetna and Blue Shield of California. We recommend calling the office directly at 713-793-3615 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Delpassand's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile